Icatibant Viatris

Icatibant, the active ingredient in Icatibant Viatris, is a Bradykinin B2 receptor antagonist presented as a subcutaneous formulation for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with confirmed diagnosis. GNH USA supplies Icatibant Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for hereditary angioedema that works by blocking the bradykinin B2 receptor pathway.

- Acute hereditary angioedema attacks: reduces swelling and pain by inhibiting bradykinin‑mediated vascular permeability. - Hereditary angioedema type I: provides rapid symptom relief during episodes. - Hereditary angioedema type II: helps control acute swelling events.

Icatibant may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Injection site pain: discomfort at the site of subcutaneous administration. - Redness or swelling at injection site: localized inflammatory response. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Severe injection site necrosis: tissue damage requiring medical attention. - Thrombocytopenia: low platelet count observed in rare cases. - Acute hypotension: sudden drop in blood pressure. - Severe abdominal pain: may indicate internal complications.

Before using Icatibant, consider the following safety measures.

- Assess patient history: verify diagnosis of hereditary angioedema and prior response to therapy. - Monitor for hypersensitivity: observe for signs of allergic reaction after injection. - Evaluate concomitant medications: consider potential additive effects on blood pressure. - Use in pregnancy and lactation: only if clearly needed, after risk‑benefit assessment by the prescriber. - Renal or hepatic impairment: adjust monitoring as appropriate. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medications; awareness of these interactions helps ensure safe use.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels, potentially reducing Icatibant efficacy. - Angiotensin receptor blockers (ARBs): similar risk of elevated bradykinin.

Moderate Interactions (Monitor Closely): - Diuretics: may affect blood pressure response. - Other B2 receptor antagonists: additive pharmacologic effects. - Antihistamines: monitor for overlapping adverse reactions.